The possibility of interactions between warfarin and dasatinib and their interactions with other drugs metabolized by cytochrome P450 isoform CYP3A4 was demonstrated using a previously created cytochrome P450 substrate—inhibitor panel for preclinical in vitro studies of drug biotransformation on a 3D histotypical microfluidic cell model of human liver (liver-on-a-chip technology). Dasatinib and warfarin are inhibitors of CYP2C19 isoform and hence, can interfere the drugs metabolized by this isoform. Our findings are in line with the data obtained on primary culture of human hepatocytes and suggest that the model can be used in preclinical in vitro studies of drugs.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aleksandrova AV, Burmistrova OA, Fomicheva KA, Sakharov DA. Maintenance of high cytochrome P450 expression in HepaRG cell spheroids in DMSO-free medium. Bull. Exp. Biol. Med. 2016;161(1):120-124.
Alexandrova AV, Pul’kova NV, Sakharov DA. Complex approach to xenobiotics hepatotoxicity testing using a microfluidic system. Bull. Exp. Biol. Med. 2016;161(1):50-53.
Au SH, Chamberlain MD, Mahesh S, Sefton MV, Wheeler AR. Hepatic organoids for microfluidic drug screening. Lab Chip. 2014;14(17):3290-3299.
Bogaards JJ, Bertrand M, Jackson P, Oudshoorn MJ, Weaver RJ, van Bladeren PJ, Walther B. Determining the best animal model for human cytochrome P450 activities: acomparison of mouse, rat, rabbit, dog, micropig, monkey and man. Xenobiotica. 2000;30(12):1131-1152.
Cheung C, Gonzalez FJ. Humanized mouse lines and their application for prediction of human drug metabolism and toxicological risk assessment. J. Pharmacol. Exp. Ther. 2008;327(2): 288-299.
Duckett DR, Cameron MD. Metabolism considerations for kinase inhibitors in cancer treatment. Expert Opin. Drug Metab. Toxicol. 2010;6(10):1175-1193.
Flockhart DA, O’Kane D, Williams MS, Watson MS, Flockhart DA, Gage B, Gandolfi R, King R, Lyon E, Nussbaum R, O’Kane D, Schulman K, Veenstra D, Williams MS, Watson MS; ACMG Working Group on Pharmacogenetic Testing of CYP2C9, VKORC1 Alleles for Warfarin Use. Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med. 2008;10(2):139-150.
Haouala A, Widmer N, Duchosal MA, Montemurro M, Buclin T, Decosterd LA. Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood. 2011; 117(8):e75-e87.
Khetani SR, Berger DR, Ballinger KR, Davidson MD, Lin C, Ware BR. Microengineered liver tissues for drug testing. J. Lab. Autom. 2015;20(3):216-250.
Langley G, Austin CP, Balapure AK, Birnbaum LS, Bucher JR, Fentem J, Fitzpatrick SC, Fowle JR 3rd, Kavlock RJ, Kitano H, Lidbury BA, Muotri AR, Peng SQ, Sakharov D, Seidle T, Trez T, Tonevitsky A, van de Stolpe A, Whelan M, Willett C. Lessons from toxicology: developing a 21st-century paradigm for medical research. Environ. Health Perspect. 2015;123(11):A268-A272.
Maltseva DV, Khaustova NA, Fedotov NN, Matveeva EO, Lebedev AE, Shkurnikov MU, Galatenko VV, Schumacher U, Tonevitsky AG. High-throughput identification of reference genes for research and clinical RT-qPCR analysis of breast cancer samples. J. Clin. Bioinforma. 2013;3(1):13. doi: 10.1186/2043-9113-3-13.
Martignoni M, Groothuis GM, de Kanter R. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin. Drug Metab. Toxicol. 2006;2(6):875-894.
Materne EM, Ramme AP, Terrasso AP, Serra M, Alves PM, Brito C, Sakharov DA, Tonevitsky AG, Lauster R, Marx U. A multi-organ chip co-culture of neurospheres and liver equivalents for long-term substance testing. J. Biotechnol. 2015;205:36-46.
Okin D, Medzhitov R. The effect of sustained inflammation on hepatic mevalonate pathway results in hyperglycemia. Cell. 2016;165(2):343-356.
Shirayama T, Shiraishi H, Kuroyanagi A, Hamaoka T, Imai M, Kojima A. Interaction between warfarin and proton pump inhibitors. Int. J. Clin. Med. 2014;5(14):836-843. doi: 10.4236/ijcm.2014.514112.
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 162, No. 10, pp. 517-522, October, 2016
Rights and permissions
About this article
Cite this article
Zakharyants, A.A., Burmistrova, O.A. & Poloznikov, A.A. The Use of Human Liver Cell Model and Cytochrome P450 Substrate—Inhibitor Panel for Studies of Dasatinib and Warfarin Interactions. Bull Exp Biol Med 162, 515–519 (2017). https://doi.org/10.1007/s10517-017-3651-z
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10517-017-3651-z